- Luigi Falco, MDDepartment of Medical Translational Sciences, University of Campania “Luigi Vanvitelli” – Monaldi Hospital, Naples, ItalyInterests: cardiovascular pharmacology; heart failure; cardiomyopathy; atrial fibrillation
The number of potential therapeutic targets for treating cardiovascular (CV) disease is growing as our understanding of its molecular principles is increased. Recent advances in CV pharmacology research have raised interest in vascular biology and further strengthen the interplay between clinical and translational investigations. For example, SGLT2i, originally developed to treat diabetes, is now currently being investigated for a wide range of other diseases, including heart failure and chronic renal disease. In addition, anticoagulants and antiplatelet drugs, where there was once a one-size fit approach, are now being abandoned in favor of patient-tailored therapies. Evidence is now emerging on new biochemical pathways and innovative cholesterol-lowering drugs. Therefore, the aim of this issue is to raise awareness among physicians on the latest advances in CV therapy.
In this Special Issue, we will focus on, and be interested in, but are not limited to, receiving manuscripts in one or more of the following areas:
(A) Updates in Heart Failure therapy
(B) Translational and therapeutic implications of new molecular pathways
(C) Personalizing antithrombotic treatment – when one size does not fit all
(D) New horizons in treating dyslipidemia
(E) Expert reviews on the latest and ongoing RCTs on cardiovascular drugs
(F) Emerging therapy of cardiomyopathies (i.e., Hypertrophic Cardiomyopathy, Transthyretin Cardiac Amyloidosis)
(G) Pharmacokinetics and pharmacodynamics features of new cardiovascular drugs
(H) Antiarrhythmic Drugs in Atrial Fibrillation
Prof. Vincenzo Russo and Luigi Falco
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- Time Trends of Etiology, Treatment, and Long-Term Outcomes Among Patients with Left Ventricular ThrombusBoqun Shi, Yanjun Song, Lie Ma, Xieraili Tiemuerniyazi, ... Ke-Fei DouRev. Cardiovasc. Med. 2023, 24(10), 298; https://doi.org/10.31083/j.rcm2410298(This article belongs to the Special Issue Cardiovascular Pharmacology)17Downloads95Views